Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.
At UT Southwestern Medical Center, we offer something unique for HCC patients – a single clinic with all of our HCC specialists available in one location. You’ll have access to whichever specialists you need, right when you need them – whether it’s a transplant hepatologist; a surgical, radiation, or medical oncologist; an interventional radiologist; or another provider – without shuffling from building to building or waiting for multiple appointments.
According to a recent study led by UT Southwestern physicians, multidisciplinary care improves treatment delivery and survival in HCC patients. But multidisciplinary clinics are rare among liver cancer programs, and the Harold C. Simmons Comprehensive Cancer Center is the only National Cancer Institute (NCI)-designated cancer center in North Texas. Our HCC team is the most experienced in the region and treats more liver cancer patients than any other facility in the area. This is important because Texas has the highest incidence rate of HCC in the country.
At a top cancer center like ours, you have options when it comes to the treatment of HCC. These options may include:
- Liver transplant
- Surgery to remove the tumor
- Stereotactic radiation therapy
- Therapies that deliver chemotherapy or radiation directly to the cancer cells
Every patient and every situation is unique, and we’ll work closely with you and each other to determine the best treatment strategy for your situation.
Screening for HCC
When HCC is caught early, it can be more easily treated and sometimes cured. Screening in high-risk patients has proven to catch HCC early and increase survival rates. If you have a condition that puts you at high risk for HCC, including cirrhosis of the liver or chronic hepatitis B or C, we can develop a regular screening program for you that will allow us to identify any developing cancer as early as possible while it’s still highly treatable.
According to published findings by UT Southwestern’s Amit Singal, M.D., liver cancer survival rates could be significantly reduced if more people with cirrhosis were screened for tumors using readily available, inexpensive, and noninvasive abdominal ultrasound scans and blood tests.
Research and Clinical Trials
UT Southwestern is a leader in liver cancer research projects, including studying optimal methods to diagnose it early, evaluating how liver cancer develops and how it can be prevented, and evaluating novel therapies for liver cancer patients. We offer clinical trials for patients with intermediate and advanced liver cancer.
Among many promising trials exploring liver cancer treatment, current trials focus on:
- Neoadjuvant therapy with transcatheter arterial chemoembolization (TACE)
- Immunotherapy treatment of hepatocellular carcinoma
Our liver cancer specialists who subspecialize in HCC include:
- Muhammed Beg, M.D.
- Sanjeeva Kalva, M.D.
- Jeffrey Meyer, M.D.
- Amit Singal, M.D.
- Adam Yopp, M.D.
- Jackie Davis (clinic navigator)
Schedule an Appointment
To schedule a visit with a hepatocellular carcinoma specialist at UT Southwestern’s facilities in Dallas or to learn more about our services, request an appointment or call 214-645-8300.